Suchergebnisse - "Tamura, Tomohide"

PubPharm (45)

1

Phase I study of TAS-121, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with non-small-cell lung cancer harboring EGFR mutations

enthalten in: Investigational new drugs | 2019

von Nishio, M. | Murakami, H. | Ohe, Y. | +11

2

A phase 2 study of lenvatinib in patients with RET fusion-positive lung adenocarcinoma

enthalten in: Lung cancer (Amsterdam, Netherlands) | 2019

von Hida, T. | Velcheti, V. | Reckamp, K. | +7

3

Multicenter, placebo-controlled, double-blind, randomized study of fosnetupitant in combination with palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy

enthalten in: Cancer | 2019

von Sugawara, S. | Inui, N. | Kanehara, M. | +10

4

Phase 1 Study of Cabozantinib in Japanese Patients With Expansion Cohorts in Non-Small-Cell Lung Cancer

enthalten in: Clinical lung cancer | 2019

von Nokihara, H. | Nishio, M. | Yamamoto, N. | +10

5

Japanese subgroup analysis of a phase III study of S-1 versus docetaxel in non-small cell lung cancer patients after platinum-based treatment : EAST-LC

enthalten in: International journal of clinical oncology | 2019

von Sugawara, S. | Nakagawa, K. | Yamamoto, N. | +19

6

Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line treatment for stage IV squamous non-small cell lung cancer : A phase 1b and randomized, open-label, multicenter, phase 2 trial in Japan

enthalten in: Lung cancer (Amsterdam, Netherlands) | 2019

von Watanabe, S. | Yoshioka, H. | Sakai, H. | +19

ErratumIn: Lung Cancer. 2019 Jun;132:157-158. - PMID 31014853

7

Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung Cancer

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2017

von Govindan, R. | Szczesna, A. | Ahn, M. | +19

CommentIn: Transl Lung Cancer Res. 2018 Feb;7(Suppl 1):S35-S38. - PMID 29531902

8

Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX) : an open-label, randomised phase 3 trial

enthalten in: Lancet (London, England) | 2017

von Hida, T. | Nokihara, H. | Kondo, M. | +20

CommentIn: Lancet. 2017 Jul 1;390(10089):3-4. - PMID 28501139

9

Three-Year Follow-Up of an Alectinib Phase I/II Study in ALK-Positive Non-Small-Cell Lung Cancer : AF-001JP

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2017

von Tamura, T. | Kiura, K. | Seto, T. | +14

10

Efficacy and safety of nivolumab in Japanese patients with advanced or recurrent squamous non-small cell lung cancer

enthalten in: Cancer science | 2017

von Hida, T. | Nishio, M. | Nogami, N. | +19

1
2
3
4
5
Nächster »
[5]